Itamar Medical Acquisition, Valuation, Funding & Investors

Tasso is a Seattle-based medical device company pioneering at-home blood collection for diagnostics. Its HemoLink device enables capillary blood sampling with 200 microliters yield in under 3 minutes, compatible with lab analyzers for therapeutic drug monitoring and wellness testing. FDA-cleared since 2020, Tasso partners with Quest Diagnostics and Everlywell, shipping over 50,000 units to consumers and clinics. Founded in 2015, the firm raised $15 million in Series A funding and operates in the US with clinical trials in Europe for chronic disease management.

Delfi Diagnostics is a Baltimore-headquartered developer of blood-based cancer screening tests using AI and genome sequencing. Its Delfi test analyzes DNA fragmentation patterns to detect lung cancer at 89 percent sensitivity in stage I cases. Clinical trials with Johns Hopkins involve over 1,000 patients, targeting multi-cancer early detection. Founded in 2019 by genome experts, the company secured FDA breakthrough designation in 2023.

Embark is a Boston-based canine genetics company offering DNA testing kits. The platform analyzes over 200,000 genetic markers using CLIA-certified SNP chips to screen for breed, health risks, traits, and preventive care recommendations, contributing to veterinary research on nutrition and diseases.

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

Precision Neuroscience is a New York-headquartered developer of brain-computer interface technology. Founded in 2021, it creates minimally invasive, removable cortical implants capable of high-resolution neural recording to treat neurological disorders affecting billions globally.

Cellanome is a Redwood City-headquartered synthetic biology platform provider. The company integrates microfluidics, sensors, and multi-omics sequencing for single-cell analysis and pathway engineering. Cellanome's system accelerates CRISPR screening by processing 10,000 variants per run. Founded in 2020, it serves early-stage biotechs in the Bay Area.

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Inscripta is a Boulder, Colorado-based gene-editing technology company, founded in 2015, that builds tools for genome engineering used in food, fuel, and healthcare applications. Its flagship product, the Onyx platform, is a benchtop system for digital microbial genome engineering that automates identifying genomic pathways, compiling them into libraries, editing them at scale with CRISPR-based tools such as the MAD7 nuclease, and analyzing the resulting effects, all within a single integrated workflow. Early commercial customers have included the University of Liverpool's GeneMill, which uses the platform to provide synthetic biology services to life-sciences and pharmaceutical partners.

GeneMind Biosciences produces third-generation single-molecule gene sequencing systems, delivering advanced tools for clinicians and researchers through ongoing technological breakthroughs.

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.

Genapsys is a genomics company delivering affordable, portable DNA sequencing systems from its Redwood City, California headquarters. Founded in 2010, it offers the GenapSys sequencer with 1.5-hour read times and cloud-based analysis for research and diagnostics. The platform supports applications in oncology, infectious disease, and agrigenomics, partnering with labs for scalable, low-cost sequencing under $1,000 per genome.

Geneoscopy is a St. Louis-based diagnostics company that offers non-invasive stool RNA tests for colorectal cancer screening using computational biology. Its ColoSense assay detects gene expression changes in human RNA extracted from stool, achieving 92 percent sensitivity for CRC and 90 percent for advanced adenomas in pivotal trials. Geneoscopy expands its platform to other gastrointestinal diseases including IBD and pancreatic cancer screening.

Sunmax Biotechnology Co Ltd is a biomedical company in Taiwan. It is engaged in the development, manufacturing, and commercialization of Sunmax medical devices and bio-surgical products. Additionally, it also researches, develops, manufactures and sales biomedical material grade collagen and related products. The company's products include medical products, biomedical materials, and porcine collagen skin care products.

Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.

MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.